Intra-Cellular Therapies 将来の成長
Future 基準チェック /66
Intra-Cellular Therapies利益と収益がそれぞれ年間68.5%と33.5%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に37.2% 68.4%なると予測されています。
主要情報
68.5%
収益成長率
68.4%
EPS成長率
Pharmaceuticals 収益成長 | 23.6% |
収益成長率 | 33.5% |
将来の株主資本利益率 | 37.2% |
アナリストカバレッジ | Good |
最終更新日 | 04 Nov 2024 |
今後の成長に関する最新情報
Recent updates
Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26%
Nov 07Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business
Sep 22Peaking Back In On Intra-Cellular Therapies
Sep 04Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 10With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For
Jul 27Intra-Cellular Brightens MDD Outlook With Caplyta Success
Jun 19Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data
Apr 16Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark
Apr 09We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Mar 17Intra-Cellular Therapies Is On Fire
Mar 11Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'
Feb 11Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues
Dec 24We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Nov 11Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth
Aug 07Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation
May 09After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar
Apr 17We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate
Jan 31Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans
Oct 25Intra-Cellular Therapies: What Lies Ahead
Sep 20Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug
Aug 22Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M
Aug 09We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely
Jul 09Intra-Cellular Therapies: A Dramatic Story
Jun 18Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth
Apr 03Intra-Cellular: Not Participating In A Bear Market
Mar 31Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand
Mar 08業績と収益の成長予測
日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
---|---|---|---|---|---|
12/31/2026 | 1,404 | 395 | 424 | 492 | 13 |
12/31/2025 | 938 | 51 | 78 | 65 | 15 |
12/31/2024 | 676 | -69 | -54 | 2 | 13 |
9/30/2024 | 614 | -86 | -63 | -62 | N/A |
6/30/2024 | 565 | -84 | -61 | -61 | N/A |
3/31/2024 | 514 | -111 | -99 | -98 | N/A |
12/31/2023 | 464 | -140 | -124 | -124 | N/A |
9/30/2023 | 420 | -155 | -162 | -161 | N/A |
6/30/2023 | 366 | -184 | -190 | -189 | N/A |
3/31/2023 | 311 | -228 | -248 | -247 | N/A |
12/31/2022 | 250 | -256 | -271 | -270 | N/A |
9/30/2022 | 188 | -298 | -305 | -304 | N/A |
6/30/2022 | 138 | -321 | -331 | -330 | N/A |
3/31/2022 | 103 | -304 | -296 | -295 | N/A |
12/31/2021 | 84 | -284 | -260 | -260 | N/A |
9/30/2021 | 71 | -259 | -255 | -255 | N/A |
6/30/2021 | 56 | -237 | -239 | -239 | N/A |
3/31/2021 | 38 | -232 | -227 | -227 | N/A |
12/31/2020 | 23 | -227 | -230 | -230 | N/A |
9/30/2020 | 10 | -207 | -196 | -197 | N/A |
6/30/2020 | 3 | -187 | -163 | -163 | N/A |
3/31/2020 | 1 | -160 | -144 | -144 | N/A |
12/31/2019 | 0 | -148 | -129 | -128 | N/A |
9/30/2019 | N/A | -148 | -123 | -122 | N/A |
6/30/2019 | N/A | -155 | -122 | -121 | N/A |
3/31/2019 | N/A | -154 | -127 | -127 | N/A |
12/31/2018 | N/A | -155 | -119 | -118 | N/A |
9/30/2018 | 0 | -145 | -115 | -114 | N/A |
6/30/2018 | 0 | -126 | N/A | -100 | N/A |
3/31/2018 | 0 | -106 | N/A | -91 | N/A |
12/31/2017 | 0 | -98 | N/A | -80 | N/A |
9/30/2017 | 0 | -95 | N/A | -84 | N/A |
6/30/2017 | 0 | -102 | N/A | -99 | N/A |
3/31/2017 | 0 | -116 | N/A | -88 | N/A |
12/31/2016 | 0 | -116 | N/A | -91 | N/A |
9/30/2016 | 0 | -118 | N/A | -98 | N/A |
6/30/2016 | 0 | -120 | N/A | -89 | N/A |
3/31/2016 | 0 | -110 | N/A | -106 | N/A |
12/31/2015 | 0 | -105 | N/A | -102 | N/A |
9/30/2015 | 0 | -91 | N/A | -73 | N/A |
6/30/2015 | 0 | -65 | N/A | -57 | N/A |
3/31/2015 | 0 | -48 | N/A | -32 | N/A |
12/31/2014 | 1 | -31 | N/A | -23 | N/A |
9/30/2014 | 1 | -24 | N/A | -25 | N/A |
6/30/2014 | 2 | -22 | N/A | -26 | N/A |
3/31/2014 | 2 | -26 | N/A | -27 | N/A |
12/31/2013 | 3 | -27 | N/A | -23 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: ITCIは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。
収益対市場: ITCI今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。
高成長収益: ITCI今後 3 年以内に収益を上げることが予想されます。
収益対市場: ITCIの収益 ( 33.5% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。
高い収益成長: ITCIの収益 ( 33.5% ) 20%よりも速いペースで成長すると予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: ITCIの 自己資本利益率 は、3年後には高くなると予測されています ( 37.2 %)